Skip to main content
MRM
NASDAQ Trade & Services

Secures $2.02M in Convertible Bonds and High-Interest Loan, Pledges Subsidiary Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Consumer
Sentiment info
Negative
Importance info
8
Price
$1.401
Mkt Cap
$11.537M
52W Low
$0.34
52W High
$4.45
52W Position info
312% above low
Off High info
69% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

MRM has more than doubled off its 52-week low of $0.34 on light trading volume (0.3× avg).

Summary

Medirom Healthcare Technologies Inc. refinanced JPY 475 million (approximately $2.02 million) of its matured corporate bonds through a new issuance of convertible bonds and a high-interest loan, securing the loan with a pledge of its subsidiary's shares.


Key Events · Financing and Capital Events · MRM

  • Convertible Bond Issuance

    Issued JPY 275 million (approximately $1.17 million) in Fourth Unsecured Convertible-Type Corporate Bonds with Share Options to Kufu Company Holdings Inc. at a 5.0% interest rate, convertible at JPY 330 per share (equivalent to the current stock price).

  • High-Interest Short-Term Loan

    Entered into a Deemed Loan Agreement for JPY 200 million (approximately $0.85 million) with Kufu Company Holdings Inc., bearing a 10.0% annual interest rate and repayable by March 31, 2026.

  • Subsidiary Shares Pledged

    Pledged all shares of its subsidiary, MEDIROM MOTHER Labs Inc. (MML), to Kufu Company Holdings Inc. as collateral for the JPY 200 million loan.

  • Debt Refinancing

    These transactions, along with a JPY 25 million cash repayment, refinanced the total JPY 500 million principal amount of the company's 1st Unsecured Convertible-Type Corporate Bonds that matured on December 31, 2025.


Analysis · MRM · Trade & Services

Medirom Healthcare Technologies Inc. has refinanced a substantial portion of its matured corporate bonds through a combination of new convertible bonds and a high-interest, short-term loan. While the convertible bonds are priced at the current market equivalent, the accompanying JPY 200 million (approximately $0.85 million) loan carries a high 10.0% annual interest rate and is due in less than two months (March 31, 2026). Critically, the company pledged all shares of its subsidiary, MEDIROM MOTHER Labs Inc., as collateral for this loan. This indicates significant financial pressure and a need for capital that required offering substantial security, raising concerns about the company's liquidity and financial health.

At the time of this filing, MRM was trading at $1.40 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $0.34 to $4.45. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MRM - Latest Insights

MRM
Jul 17, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.9301
Real-time Price: $0.950 info
Change: +$0.0199 (+2%) info
Market Cap: $7.271M info
MRM
Jun 25, 2026, 5:00 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.04
Real-time Price: $0.950 info
Change: -$0.090 (-9%) info
Market Cap: $7.271M info
MRM
Jun 25, 2026, 4:00 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.01
Real-time Price: $0.950 info
Change: -$0.060 (-6%) info
Market Cap: $7.271M info
MRM
May 29, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.12
Real-time Price: $0.950 info
Change: -$0.170 (-15%) info
Market Cap: $7.271M info
MRM
May 28, 2026, 4:13 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $1.20
Real-time Price: $0.950 info
Change: -$0.250 (-21%) info
Market Cap: $7.271M info